Angels for Change Partners with Mark Cuban Cost Plus Drug Company to Combat Oncology Drug Shortages

June 25, 2025 07:58 AM AEST | By EIN Presswire
 Angels for Change Partners with Mark Cuban Cost Plus Drug Company to Combat Oncology Drug Shortages
Image source: EIN Presswire
TAMPA, FL, UNITED STATES, June 24, 2025 /EINPresswire.com/ -- In a decisive move to safeguard pediatric cancer patients from life-threatening drug shortages, Angels for Change has awarded a 2025 Project PROTECT grant to a 503B Outsourcing Facility operated by the Mark Cuban Cost Plus Drug Company.

This groundbreaking partnership will fast-track the production of two essential chemotherapy drugs—Carboplatin Injection and Methotrexate Injection—both currently in critical national shortage. By expanding onshore manufacturing and supply readiness, the collaboration aims to ensure timely access to these life-saving medications for patients and healthcare providers across the country during shortage.

This marks the first collaboration between the patient advocacy nonprofit and Mark Cuban Cost Plus Drug Company who share a mission to prevent and mitigate drug shortages.

Through Project PROTECT, we’re proactively safeguarding patients from drug shortages before they become crises,” said Laura Bray, Founder and Chief Change Maker of Angels for Change. “Partnering with trusted innovators like Mark Cuban Cost Plus ensures that even during supply chain disruptions, patients can access the medications they depend on without delays.”

A Proactive Approach to Prevention
Launched in 2022, Project PROTECT (Proactive Response to Essential Drug Shortages through End-to-End Coordination and Trust) is the only national program that funds pharmaceutical production before shortages reach critical levels. By leveraging predictive data and strategic onshore manufacturing partnerships, the initiative creates a robust safety net for at-risk medications.

The 2025 grant will support targeted infrastructure investments and expanded manufacturing of Carboplatin and Methotrexate—two cornerstone drugs in cancer treatment protocols.

“These medications are essential to cancer care,” said Alex Oshmyansky, Founder & CEO, Mark Cuban Cost Plus Drug Company. “We are proud to work alongside Angels for Change to help ensure they remain available for every patient who needs them.”

Building a Resilient Future for Patient Access
PROTECT represents a new standard in pharmaceutical supply chain resilience—focusing on transparency, early intervention, and patient-first solutions. By anticipating potential shortages and investing in readiness, Angels for Change and Mark Cuban Cost Plus are reshaping how the healthcare system protects access to vital medications.

About Project PROTECT
Project PROTECT is a national initiative that provides grants to 503B Outsourcing Facilities to proactively manufacture essential medications at risk of shortage. Learn more: www.angelsforchange.org/project-protect

About Angels for Change
Angels for Change is a nonprofit patient advocacy organization dedicated to ending drug shortages through advocacy, awareness, and a more resilient pharmaceutical supply chain. Learn more: www.angelsforchange.org

About Mark Cuban Cost Plus Drug Company
The Mark Cuban Cost Plus Drug Company is committed to making medications more affordable and accessible by offering them at transparent, low-cost prices. The company partners directly with manufacturers to help fix the broken pharmaceutical supply chain. Learn more: www.markcubancostplusdrugcompany.com

Laura Bray
Angels for Change
+1 813-501-7742
email us here
Visit us on social media:
LinkedIn
Instagram
Facebook

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.


Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Pty Ltd (“Kalkine Media, we or us”), ACN 629 651 672 and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary.
The content published on Kalkine Media also includes feeds sourced from third-party providers. Kalkine does not assert any ownership rights over the content provided by these third-party sources. The inclusion of such feeds on the Website is for informational purposes only. Kalkine does not guarantee the accuracy, completeness, or reliability of the content obtained from third-party feeds. Furthermore, Kalkine Media shall not be held liable for any errors, omissions, or inaccuracies in the content obtained from third-party feeds, nor for any damages or losses arising from the use of such content.
Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used on this website are copyrighted to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have made reasonable efforts to accredit the source wherever it was indicated as or found to be necessary.
This disclaimer is subject to change without notice. Users are advised to review this disclaimer periodically for any updates or modifications.


AU_advertise

Advertise your brand on Kalkine Media

Sponsored Articles


Investing Ideas

Previous Next
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.